ZTSMEDIUM SIGNALFINANCIAL10-K

Zoetis substantially increased share buybacks while undertaking significant balance sheet restructuring that reduced stockholders' equity by 30%.

The company's aggressive capital return strategy, with share buybacks increasing meaningfully year-over-year, signals management's confidence in cash generation but also contributed to a notable decline in stockholders' equity. The planned 2026 fiscal year alignment for international subsidiaries suggests operational streamlining efforts to improve reporting consistency and potentially enhance operational efficiency.

Comparing 2026-02-12 vs 2025-02-13View on EDGAR →
FINANCIAL ANALYSIS

Zoetis executed an aggressive capital return program with substantially higher share buybacks, while simultaneously restructuring its balance sheet as evidenced by a 28% increase in total liabilities and a 30% reduction in stockholders' equity. The company strengthened its working capital position with current assets growing 13% and current liabilities declining 35%, alongside a 21% increase in accounts receivable. This financial profile suggests active balance sheet management focused on returning capital to shareholders while maintaining operational liquidity.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
+74.1%
$1.9B→$3.2B

Share repurchases increased 74.1% — management returning capital, signals confidence in intrinsic value.

Current Liabilities
Balance Sheet
-34.5%
$3.4B→$2.2B

Current liabilities reduced — improved short-term financial position and working capital health.

Stockholders Equity
Balance Sheet
-30.2%
$4.8B→$3.3B

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Total Liabilities
Balance Sheet
+28.2%
$9.5B→$12.1B

Liabilities increased 28.2% — monitor debt-to-equity ratio and interest coverage.

Accounts Receivable
Balance Sheet
+20.8%
$1.3B→$1.6B

Receivables grew 20.8% — monitor days sales outstanding for collection efficiency.

Current Assets
Balance Sheet
+13.1%
$6.0B→$6.8B

Current assets grew 13.1% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2026-02-12
PRIOR — 2025-02-13
ADDED
With a legacy of nearly 75 years, we continue to pioneer ways to predict, prevent, detect, and treat animal illness, supporting those raising and caring for animals worldwide - from veterinarians and pet owners to livestock producers.
As a result of these differences, among other things, we organize and operate our business in two segments: United States (U.S.) with revenue of $5,097 million, or 54% of total revenue for the year ended December 31, 2025; and International with revenue of $4,254 million, or 45% of total revenue for the year ended December 31, 2025.
In 2026, we expect to eliminate the one-month lag in reporting of our subsidiaries operating outside the U.S.
and align the fiscal years of the subsidiaries within our U.S.
segment and the subsidiaries within our International segment.
For additional information regarding the expected fiscal year alignment of our subsidiaries operating outside the U.S.
Companion animal products represented approximately 70% of our revenue for the year ended December 31, 2025.
Livestock products represented approximately 29% of our revenue for the year ended December 31, 2025.
For example, the first product in our Simparica (sarolaner) product line, a monthly oral chewable tablet to prevent fleas and ticks, was launched in February 2016.
In 2020, we expanded the franchise with Simparica Trio , which combines sarolaner with moxidectin and pyrantel, expanding the spectrum of protection for dogs to include fleas, ticks, heartworm and gastro-intestinal nematodes.
REMOVED
For over 70 years, we have been innovating ways to predict, prevent, detect, and treat animal illness, and continue to stand by those raising and caring for animals worldwide - from veterinarians and pet owners to livestock producers.
As a result of these differences, among other things, we organize and operate our business in two segments: United States (U.S.) with revenue of $5,074 million, or 55% of total revenue for the year ended December 31, 2024; and International with revenue of $4,102 million, or 44% of total revenue for the year ended December 31, 2024.
Companion animal products represented approximately 68% of our revenue for the year ended December 31, 2024.
Livestock products represented approximately 31% of our revenue for the year ended December 31, 2024.
For example, the first product in our ceftiofur line was an anti-infective approved for treating bovine respiratory disease (BRD) in cattle that was administered via intramuscular injection.
Through follow-on studies and reformulations, we have expanded the product line into additional cattle claims and administration routes, as well as other species and regions.
The ceftiofur product line currently includes the brands Excede , Excenel , Naxcel and Spectramast .
in 2018 and in Canada in 2019; Cytopoint , the first canine monoclonal antibody (mAb) to help reduce the clinical signs of atopic dermatitis (such as itching) in dogs of any age, was licensed in the U.S.
An injection given once every four to eight weeks, Cytopoint neutralizes interleukin-31, a protein that has been demonstrated to trigger itching in dogs; Fostera PCV MH was introduced in November 2013 in the U.S.
This vaccine offers protection against both the respiratory and reproductive forms of disease caused by porcine reproductive and respiratory syndrome (PRRS) virus; Librela (bedinvetmab), the first and only injectable mAb therapy for monthly alleviation of osteoarthritis (OA) pain in dogs, was approved in the EU in 2020 and has since been approved in other key markets globally, including the U.S.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →